• 09 Feb 2026
• Admin
• News Article

US FDA Grants Orphan Drug Designation to Zydus’ Desidustat for Sickle Cell Disease

Zydus Lifesciences Limited has received Orphan Drug Designation (ODD) from the US Food and Drug Administration for desidustat, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of sickle cell disease (SCD).

The designation is granted by the FDA’s Office of Orphan Drug Products to support development of therapies for rare diseases affecting fewer than 200,000 patients in the US.

Why This Matters in Sickle Cell Disease?

Sickle cell disease remains an area of significant unmet medical need, with limited and imperfect treatment options.

Limitations of Current Therapies

• Hydroxyurea
  • Reduces frequency of painful crises
  • Not effective in all patients
  • Associated with adverse effects such as:
    • Neutropenia
    • Thrombocytopenia
• Blood transfusions
  • High cost and limited accessibility
  • Clinical risks including:
    • Alloimmunization
    • Hemolysis
    • Iron overload

Despite advances, many patients continue to experience disease complications and poor quality of life.

Desidustat: A Novel Oral Approach

Desidustat is an oral HIF-PHI, a drug class that modulates oxygen-sensing pathways and has potential to address underlying disease mechanisms in SCD.

• Phase II clinical progress
  • A double-blind, randomized, placebo-controlled, multicentre proof-of-concept study has been completed
  • Evaluated both efficacy and safety in patients with SCD
  • Study results are expected to be published in a peer-reviewed medical journal

Regulatory and Development Advantages of ODD

Orphan Drug Designation provides Zydus with several regulatory and commercial incentives, including:

• Tax credits for qualified clinical trial costs
• Waiver of FDA prescription drug user fees
• Seven years of market exclusivity in the US following FDA approval

These incentives are designed to accelerate development timelines for rare disease therapies.

Strategic Significance for Zydus

According to Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited, the designation underscores the urgent need for new treatment options in sickle cell disease.

From a pipeline perspective, this designation:

• Strengthens Zydus’ innovation-led portfolio
• Expands its footprint in rare and complex diseases
• Positions desidustat as a potential first-in-class oral option in SCD management

Big Picture Takeaway

The FDA’s Orphan Drug Designation for desidustat signals growing regulatory recognition of the treatment gaps in sickle cell disease. If clinical data supports its promise, desidustat could:

• Offer a non-transfusion, oral therapeutic alternative
• Reduce reliance on treatments with significant safety and access challenges
• Advance Zydus’ ambitions in global specialty and rare disease markets

If you want, I can:

• Stress-test desidustat’s positioning vs emerging SCD therapies
• Convert this into an investor note or regulatory tracker update

Map how ODD could influence US launch economics and timelines